Literature DB >> 17565609

Effects of CD40 binding on ovarian carcinoma cell growth and cytokine production in vitro.

O Toutirais1, A Gervais, F Cabillic, M Le Gallo, A Coudrais, J Levêque, V Catros-Quemener, N Genetet.   

Abstract

The poor prognosis associated with ovarian carcinoma (OVCA) is linked to the high incidence of local recurrence. There is a pressing need to identify factors that can play a role in OVCA growth and spread. Here, we focused on CD40, a member of the tumour necrosis factor (TNF) receptor superfamily with important functions in immune response. The expression of CD40 has been reported on various types of carcinoma cells, but its biological role is still poorly understood. The aim of the present study was to investigate the expression and function of the CD40 in OVCA cell lines. Detectable CD40 levels ranging from low to very high were found on the cell surface of several OVCA cell lines by flow cytometry analysis. Co-culture with a murine cell line transfected with CD40 ligand (CD40L) inhibited cell growth and up-regulated the secretion of proinflammatory cytokines interleukin (IL)-6, IL-8 and TNF-alpha in high-level CD40-expressing OVCA cell lines. Similarly, an increase of IL-6 and IL-8 release could be obtained by adding a soluble form of CD40L to the OVCA cultures. These results suggest that CD40-CD40L interaction is an important pathway affecting growth regulation and cytokine production in OVCA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17565609      PMCID: PMC1941941          DOI: 10.1111/j.1365-2249.2007.03426.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation.

Authors:  F Sbih-Lammali; B Clausse; H Ardila-Osorio; R Guerry; M Talbot; S Havouis; L Ferradini; J Bosq; T Tursz; P Busson
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

2.  T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

Authors:  S P Schoenberger; R E Toes; E I van der Voort; R Offringa; C J Melief
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

3.  Expression of the co-stimulatory molecule CD40 on melanoma cells.

Authors:  W D Thomas; M J Smith; Z Si; P Hersey
Journal:  Int J Cancer       Date:  1996-12-11       Impact factor: 7.396

4.  Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand.

Authors:  A Hirano; D L Longo; D D Taub; D K Ferris; L S Young; A G Eliopoulos; A Agathanggelou; N Cullen; J Macartney; W C Fanslow; W J Murphy
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

5.  Activation of CD40 favors the growth and vascularization of Kaposi's sarcoma.

Authors:  L Biancone; V Cantaluppi; M Boccellino; L Del Sorbo; S Russo; A Albini; I Stamenkovic; G Camussi
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

Review 6.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

7.  Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma.

Authors:  N H Obata; K Tamakoshi; K Shibata; F Kikkawa; Y Tomoda
Journal:  Anticancer Res       Date:  1997 Jan-Feb       Impact factor: 2.480

8.  Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-1 (CD95)-induced apoptosis.

Authors:  E Jakobson; G Jönsson; P Björck; S Paulie
Journal:  Int J Cancer       Date:  1998-09-11       Impact factor: 7.396

Review 9.  CD40 and epithelial cells: across the great divide.

Authors:  L S Young; A G Eliopoulos; N J Gallagher; C W Dawson
Journal:  Immunol Today       Date:  1998-11

10.  Fas ligation induces apoptosis of CD40-activated human B lymphocytes.

Authors:  P Garrone; E M Neidhardt; E Garcia; L Galibert; C van Kooten; J Banchereau
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Immunotherapy for ovarian cancer: what's next?

Authors:  Lana E Kandalaft; Daniel J Powell; Nathan Singh; George Coukos
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

Review 2.  The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Authors:  Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos
Journal:  Gynecol Oncol       Date:  2009-12-02       Impact factor: 5.482

3.  Cationic liposome-mediated transfection of CD40 ligand gene inhibits hepatic tumor growth of hepatocellular carcinoma in mice.

Authors:  Yong-fang Jiang; Jing Ma; Yan He; Yong-hong Zhang; Yun Xu; Guo-zhong Gong
Journal:  J Zhejiang Univ Sci B       Date:  2009-01       Impact factor: 3.066

4.  CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells.

Authors:  X Qiu; C Klausen; J-C Cheng; P C K Leung
Journal:  Cell Death Dis       Date:  2015-08-27       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.